MedTrace Logo

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

NCT00577356 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2011-01-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out what effects, good and bad, the combination of docetaxel with CG1940/CG8711 (immunotherapy drugs) have on destroying prostate cancer before removal the prostate (prostatectomy).

Conditions

Interventions

DRUG

Docetaxel

Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.

BIOLOGICAL

CG1940/CG8711

Immunotherapy allogeneic GM-CSF secreting cellular vaccine

Sponsors & Collaborators

  • Cell Genesys

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • Benaroya Research Institute

    lead OTHER

Principal Investigators

  • Jacqueline Vuky, MD · Virginia Mason Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00577356 on ClinicalTrials.gov